Drug Profile
Blosozumab - Eli Lilly
Alternative Names: LY-2541546; TST-002Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Transcenta Holding
- Class Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action SOST protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Postmenopausal osteoporosis
- Phase I Osteoporosis